Inventor

FERRARA NAPOLEONE

US96 patents

⚠️ This page may combine multiple inventors who share the name “FERRARA NAPOLEONE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

FERRARA NAPOLEONE

GENENTECH INC

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production

Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production

Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Chimeric receptors as inhibitors of vascular endothelial growth factor activity, and processes for their production

Methods for using chimeric vascular endothelial growth factor receptor proteins

Humanized anti-TGF-beta antibodies

Variants of vascular endothelial cell growth factor

Nucleic acids encoding variants of vascular endothelial cell growth factor

Production of vascular endothelial cell growth factor and DNA encoding same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)

Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Nucleic acid encoding PRO211 polypeptides

Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Uses of VEGF-E

Tie receptor tyrosine kinase ligand homologues

Angiogenesis using hepatocyte growth factor

Nucleic acids encoding NL-3

Method of treating heart failure using leukemia inhibitory factor antagonists optionally with endothelin antagonists

Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy

Inhibitors of angiopoietin-like 4 protein, combinations, and their use

EG-VEGF nucleic acids and polypeptides and method of use

Composition comprising and method of using angiopoietin-like protein 3 Angptl3

Humanized anti-TGF-beta antibodies

Variants of vascular endothelial cell growth factor, their uses, and processes for their production

Variants of vascular endothelial cell growth factor

Anti-pro211 polypeptide antibodies

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

PRO363 polypeptides

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

Secreted and transmembrane polypeptides and nucleic acids encoding the same

EG-VEGF nucleic acids and polypeptides and methods of use

UNIV CALIFORNIA

Long-acting VEGF inhibitors for intraocular neovascularization

Long-acting VEGF inhibitors for intraocular neovascularization

Long-acting VEGF inhibitors for intraocular neovascularization

DAVIS-SMYTH TERRI LYNN

Methods of inhibiting vascular endothelial growth factor activity

Inhibitors of vascular endothelial growth factor activity

FERRARA NAPOLEONE

Transgenic mice expressing humanized VEGF

Composition comprising and method of using angiopoietin-like protein 3 ANGPTL3